Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
Transperineal focal laser ablation (FLA) is a specialized medical procedure designed for the targeted destruction of malignant prostate tissue. This technique utilizes focused laser energy to thermally ablate cancerous cells while preserving the surrounding healthy prostate tissue. The procedure is characterized as minimally invasive, allowing it to be performed on an outpatient basis, which typically results in a lower risk of side effects compared to more traditional surgical methods. FLA can be repeated if necessary, providing flexibility in treatment options for patients. During the procedure, the malignant tissue absorbs the laser light energy, which induces heat within a matter of seconds, leading to the destruction of the targeted cells. The effectiveness of the procedure is influenced by several factors, including the temperature, duration of heat transfer, and the depth of light distribution, all of which are determined by the specific wavelength of the laser used. To facilitate the procedure, a Foley catheter is placed, and an ultrasound probe is inserted into the rectum, usually under intravenous sedation combined with a local anesthetic. A percutaneous catheter is then inserted through the perineum to deliver an optical fiber equipped with a diffusing tip and a diode laser, which is surrounded by a cooling system connected to a flow circuit of sterile saline at room temperature. The precise location of the cancerous tissue is identified using contrast-enhanced ultrasonography or three-dimensional ultrasound, guided by MRI-fused images. Initially, the laser is activated at a lower power level to confirm the correct placement before the full treatment begins. Throughout the procedure, real-time monitoring of tissue necrosis and temperature around the treatment area is conducted to ensure safety, with the system programmed to terminate laser delivery if critical structures reach predetermined temperature limits. After the procedure, the Foley catheter is removed, and the patient is monitored for a period before being discharged.
© Copyright 2026 Coding Ahead. All rights reserved.
The transperineal focal laser ablation procedure is indicated for patients diagnosed with malignant prostate tissue. This procedure is particularly suitable for individuals who require targeted treatment of prostate cancer while minimizing damage to surrounding healthy tissue. The use of focal laser ablation is often considered for patients who may benefit from a less invasive approach compared to traditional surgical options, especially those who are looking for a procedure that can be repeated in the future if necessary.
The transperineal focal laser ablation procedure involves several key steps to ensure effective treatment of malignant prostate tissue. Initially, a Foley catheter is placed to facilitate urine drainage during the procedure. Following this, an ultrasound probe is inserted into the rectum to provide imaging guidance. This is typically done under intravenous sedation combined with a local anesthetic to ensure patient comfort. A percutaneous catheter is then inserted through the perineum, which allows for the delivery of an optical fiber equipped with a diffusing tip and a diode laser. This fiber is surrounded by a cooling system that is connected to a flow circuit of room-temperature sterile saline, which helps to protect surrounding tissues from excessive heat during the procedure. Next, the precise location of the cancerous tissue is identified using contrast-enhanced ultrasonography or three-dimensional ultrasound, guided by MRI-fused images. This imaging is crucial for accurately targeting the malignant area. Once the laser fiber is positioned correctly, the laser is initially activated at a reduced power level to verify proper placement. After confirming the correct positioning, the treatment is initiated, and the laser delivers energy to the targeted tissue. Throughout the procedure, real-time monitoring of tissue necrosis and temperature around the treatment area is conducted to ensure safety. The system is designed to automatically terminate laser delivery if temperatures at critical structures reach the assigned limit, thereby preventing potential damage. Upon completion of the procedure, the Foley catheter is removed, and the patient is monitored for a period to ensure stability before being discharged.
After the transperineal focal laser ablation procedure, patients are typically monitored for a short period to ensure that they are stable and recovering well. The removal of the Foley catheter marks the conclusion of the procedure, and patients may experience some discomfort or mild side effects, which should be managed appropriately. It is important for patients to follow any post-procedure care instructions provided by their healthcare team, which may include recommendations for activity levels, hydration, and signs of complications to watch for. Patients are usually advised to schedule follow-up appointments to assess the effectiveness of the treatment and to monitor for any recurrence of prostate cancer.
| Short Descr | TPRNL FOCAL ABLTJ MAL PRST8 | Medium Descr | TRANSPERINEAL FOCAL LASER ABLTJ MAL PRST8 TISS | Long Descr | Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging | Status Code | Carriers Price the Code | Global Days | YYY - Carrier Determines Whether Global Concept Applies | PC/TC Indicator (26, TC) | 0 - Physician Service Code | Multiple Procedures (51) | 2 - Standard payment adjustment rules for multiple procedures apply. | Bilateral Surgery (50) | 0 - 150% payment adjustment for bilateral procedures does NOT apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 1 - Statutory payment restriction for assistants at surgery applies to this procedure... | Co-Surgeons (62) | 0 - Co-surgeons not permitted for this procedure. | Team Surgery (66) | 0 - Team surgeons not permitted for this procedure. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Hospital Part B services paid through a comprehensive APC | ASC Payment Indicator | Non office-based surgical procedure added in CY 2008 or later; payment based on OPPS relative payment weight. | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
| 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2022-01-01 | Added | First appearance in codebook. |
| 2021-07-01 | Added | Code added. |
Get instant expert-level medical coding assistance.